Mylan Announces Tentative Approval for Finasteride Tablets USP, 5mg
Posted on: Tuesday, 18 April 2006, 09:01 CDT
PITTSBURGH, April 18 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for Finasteride Tablets USP, 5mg. Finasteride Tablets are the AB-rated generic equivalent of Merck's Proscar(R) Tablets, 5 mg, which had annual U.S. sales of approximately $390 million as of December 31, 2005, according to IMS Health.
About Mylan Laboratories
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit http://www.mylan.com/.
Mylan Laboratories Inc.
CONTACT: Media, Patrick Fitzgerald., or Investors, Kris King, of MylanLaboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com/
Source: PRNewswire-FirstCall
Related Articles
- Mylan Laboratories: Acquisition Creates a Top-Three Generic Player
- Schaeffer's Upon Further Review Highlights the Following Stocks: Amazon.Com, Google, eBay, Travelzoo, and Mylan Laboratories
- Mylan Laboratories Appoints Carolyn Myers, Ph.D., President of Mylan Technologies Inc.
- Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement
- Mylan Announces Final Approval for Bisoprolol Fumarate Tablets, USP
- Mylan Announces Final FDA Approval for Glimepiride Tablets
- Mylan Laboratories Inc. Reports Positive Development From FDA Advisory Committee Vote on EMSAM(R)
- Mylan Laboratories Inc. Announces Executive Appointments
- Drugmaker Mylan Laboratories Reports Decline in Earnings, Revenue
- Mylan Receives Approval for Mercaptopurine Tablets USP, 50 Mg
 |
 |
User Comments (0)
RSS Feeds